BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease
June 24 2020 - 5:30AM
BriaCell Therapeutics Corp. (“BriaCell” or the “Company”)
(TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, announces that it has filed a provisional patent
application with the U.S. Patent and Trademark Office (USPTO)
outlining compositions and methods of developing novel multi-valent
decoy receptors for diagnosis and treatment of coronavirus
infection.
The patent application, entitled “MULTI-VALENT
DECOY RECEPTORS FOR DIAGNOSIS AND/OR TREATMENT OF CORONAVIRUS
INFECTION”, describes a platform to generate multi-valent molecular
constructs (decoy receptors) that have the potential to prevent
coronaviruses including the SARS-CoV-2 virus (the virus that causes
Coronavirus Disease 2019 (COVID-19)) from entering (infecting)
healthy host cells. Multi-valent constructs described in the patent
application are believed to have both therapeutic and diagnostic
potential, the latter in the context of determining whether a
patient has developed coronavirus-specific antibodies. The Company
cautions that these novel therapeutics are still under early-stage
research and development and is not making any express or implied
claims as to their success in treatment or commercial viability.
The patent application seeks protection for, among others, the
design of new therapeutics and diagnostics and methods for their
use.
BriaCell has recently filed three other
provisional patent applications related to treatments for
Coronavirus including: (1) genetically engineered whole-cell
immunotherapy (2) antibody-based treatment; and (3) antigen-based
induction of immune response:
Patent Application 1 (April 14, 2020 press
release): Genetically Engineered Whole-Cell Immunotherapy
- “INDUCING IMMUNE RESPONSES BY TRANSFORMING CANCER CELLS INTO
ANTIGEN-PRESENTING CELLS”;
- Antigen-presenting cells are the cells that typically start
immune responses. BriaCell’s whole-cell immunotherapies are
designed to stimulate the immune system to recognize and destroy
the patient’s tumors by acting as antigen-presenting cells that
turn on cancer cell-recognizing immune cells from the patient.
Patent Application 2 (April 21, 2020 press
release): Antibody-Based Approach
- “COMPUTER-GUIDED DESIGN OF ANTIBODIES INCLUDING NEUTRALIZING
SARS-CoV-2 BINDING AGENTS”;
- Antibodies designed and selected to neutralize SARS-CoV-2 using
computer simulation – envisioned to prevent and treat the
life-threatening symptoms of COVID-19;
- BriaCell hypothesizes that antibodies may quickly and
specifically recognize the SARS-CoV-2 virus, bind to it, and
neutralize it.
Patent Application 3 (May 20, 2020 press
release): Antigen-Based Approach
- “MULTI-VALENT IMMUNOSTIMULATORS FOR INFECTIOUS DISEASES,
AUTOIMMUNE DISEASES, ALLERGIC DISEASES AND CANCER”;
- Platform to generate multi-valent reagents carrying an antigen
(such as an antigen from SARS-CoV-2) and delivering it to immune
cells to induce (or dampen) immune responses;
- Anticipated effect is a targeted therapy envisioned to
selectively destroy infectious agents or cancer cells with minimal
negative effect on normal cells.
The Company cautions that COVID-19 therapeutic
development is still under early-stage research and development and
is not making any express or implied claims that it has the ability
to treat, prevent or eliminate the COVID-19 virus at this time. The
Company notes that it will be relying on third parties for part of
this research.
The Company’s scientific experts have read and
approved the scientific disclosures contained in the press
release.
About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but
are not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics
Corp.:Farrah DeanManager, Corporate DevelopmentEmail:
farrah@BriaCell.com Phone: 1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024